These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32776377)

  • 21. Xenotransplantation in Australia: Development of the regulatory process.
    Hawthorne WJ; Cowan PJ
    Xenotransplantation; 2020 May; 27(3):e12603. PubMed ID: 32506483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory aspects of clinical xenotransplantation.
    Schuurman HJ
    Int J Surg; 2015 Nov; 23(Pt B):312-321. PubMed ID: 26408947
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tobacco regulatory science: research to inform regulatory action at the Food and Drug Administration's Center for Tobacco Products.
    Ashley DL; Backinger CL; van Bemmel DM; Neveleff DJ
    Nicotine Tob Res; 2014 Aug; 16(8):1045-9. PubMed ID: 24638850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Xenotransplantation at the crossroads.
    Pierson RN
    Xenotransplantation; 2004 Sep; 11(5):391-3. PubMed ID: 15303974
    [No Abstract]   [Full Text] [Related]  

  • 25. The porcine virome and xenotransplantation.
    Denner J
    Virol J; 2017 Sep; 14(1):171. PubMed ID: 28874166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The US Food and Drug Administration and probiotics: regulatory categorization.
    Degnan FH
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S133-6; discussion S144-51. PubMed ID: 18181719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
    Oner ZG; Michel SLJ; Polli JE
    Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Xenotransplantation: proceed with caution.
    Nasto B
    Nat Biotechnol; 1996 Apr; 14(4):424, 426. PubMed ID: 9630910
    [No Abstract]   [Full Text] [Related]  

  • 29. From the Food and Drug Administration.
    Nightingale SL
    JAMA; 1996 Nov; 276(20):1632. PubMed ID: 8922440
    [No Abstract]   [Full Text] [Related]  

  • 30. Xenotransplantation--caution, but no moratorium.
    Sachs DH; Colvin RB; Cosimi AB; Russell PS; Sykes M; McGregor CG; Platt JL
    Nat Med; 1998 Apr; 4(4):372-3. PubMed ID: 9546765
    [No Abstract]   [Full Text] [Related]  

  • 31. Probiotic foods and drugs: impact of US regulatory status on design of clinical trials.
    Hibberd PL; Davidson L
    Clin Infect Dis; 2008 Feb; 46 Suppl 2():S137-40; discussion S144-51. PubMed ID: 18181720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xenotransplantation in orthopaedic surgery.
    Laurencin CT; El-Amin SF
    J Am Acad Orthop Surg; 2008 Jan; 16(1):4-8. PubMed ID: 18180387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Partnership of the International Xenotransplantation Association, The Transplantation Society, and World Health Organization in the development of guidance documents and policies for xenotransplantation including the Changsha communiqué.
    Hawthorne WJ
    Xenotransplantation; 2020 May; 27(3):e12604. PubMed ID: 32449210
    [No Abstract]   [Full Text] [Related]  

  • 34. FDA regulatory pathways for knee cartilage repair products.
    Levine DW; Mondano L; Halpin M
    Sports Med Arthrosc Rev; 2008 Dec; 16(4):202-7. PubMed ID: 19011551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Establishment registration and listing for manufacturers of human cellular and tissue-based products--FDA. Proposed rule; reopening of comment period.
    Fed Regist; 1998 Dec; 63(237):68212-3. PubMed ID: 10338885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xenotransplantation in the new millennium: moratorium or cautious experimentation?
    Kumar PD
    Perspect Biol Med; 2000; 43(4):562-76. PubMed ID: 11058992
    [No Abstract]   [Full Text] [Related]  

  • 37. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
    O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
    Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory requirements of the Food and Drug Administration would preclude product claims based on observational research.
    Griffin JP; Godfrey BM; Sherman RE
    Health Aff (Millwood); 2012 Oct; 31(10):2188-92. PubMed ID: 23048095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Legal regulation of the production and trade of medical devices and medical equipment in the EU and US: experience for Ukraine.
    Pashkov V; Kotvitska A; Harkusha A
    Wiad Lek; 2017; 70(3 pt 2):614-618. PubMed ID: 28713093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory aspects of xenotransplantation in Korea.
    Kwon I; Park CG; Lee S
    Xenotransplantation; 2020 May; 27(3):e12602. PubMed ID: 32420655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.